-
05:51:42 AM
Sign in with email
Forgot your password?
Register with email
Account Verification

EQ Stock News

05/12/22 4:01 PM
Nasdaq : EQ
earningsclinical triallow float
Equillium Reports First Quarter 2022 Financial Results and Provides Corporate and Clinical Development Updates
Equillium, Inc., a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced financial results for the first quarter 2022 and provided an update on its corporate development and clinical programs. “It’ s been a transformative start to...
RHEA-AI
neutral
04/25/22 8:00 AM
Nasdaq : EQ
low float
Equillium Announces Three Poster Presentations at the Transplantation & Cellular Meetings of the ASTCT and CIBMTR
Equillium, Inc., a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that three posters were presented over the weekend at the Transplantation& Cellular Meetings of the American Society of Transplantation and Cellular...
RHEA-AI
neutral
03/23/22 4:01 PM
Nasdaq : EQ
earningsclinical triallow float
Equillium Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate & Clinical Development Updates
Equillium, Inc., a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced financial results for the fourth quarter and full year 2021 and provided corporate and clinical development updates. “I’ m proud of our team and the progress we...
RHEA-AI
neutral
03/23/22 8:00 AM
Nasdaq : EQ
low float
Equillium Announces Two Oral Presentations at the Annual Meeting of the European Society for Blood and Marrow Transplantation
Equillium, Inc., a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced two oral presentations at the 48th Annual Meeting of the European Society for Blood and Marrow Transplantation. Clinical data were presented by Corey...
RHEA-AI
positive
03/04/22 8:00 AM
Nasdaq : EQ
clinical triallow float
Equillium Announces Initiation of the Phase 3 EQUATOR Study of Itolizumab in First-line Acute Graft-Versus-Host Disease
Equillium, Inc., a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced the initiation of the EQUATOR study, a pivotal Phase 3 clinical study of itolizumab in patients with acute graft-versus-host disease.
RHEA-AI
positive